"Swap bio" Launches a facility to produce advanced oncology drugs

Abu Dhabi, December 16 / WAM / Mubadala Bio, the national company specializing in pharmaceutical manufacturing that aims to strengthen the pharmaceutical manufacturing system in the UAE, announced the opening of the highly effective pharmaceutical facility affiliated with its company, Bioventure Healthcare, and the launch of three essential drugs for the treatment of oncology, some of which are produced locally for the first time as alternative medicines.

This step represents a pivotal achievement in the process of developing the pharmaceutical system in the UAE and ensuring the continued availability and ease of access to vital treatments.

The facility was designed with international specifications specifically to deal with complex and highly effective pharmaceutical products, including oncology and hormone drugs, and was built according to the highest safety and quality standards to match the requirements of international specifications.

The first drugs to be launched at this facility include: “Lenalidomide,” which is used to treat multiple myeloma, a type of blood cancer, and “Pomalidomide,” which is a drug produced locally for the first time in the UAE, and is also used to treat multiple myeloma, as it provides an additional treatment option to control the disease, and “Sunitinib,” which is a targeted therapy used to treat specific types of advanced cancer. Or aggravated.

By providing these vital medicines in the local market, Mubadala Bio contributes to enhancing drug security, ensuring continuity of supply, and providing more cost-efficient treatment options to patients across the UAE.

Dr. Bakhit Al Kathiri, CEO of the UAE Investment Sector at Mubadala, and Chairman of the Board of Directors of “Mubadala Bio”, said that the launch of these drugs locally for the treatment of oncology is an important addition to the growing “Mubadala Bio” portfolio, and contributes to developing the pharmaceutical industries in the country and enhancing its progress, in addition to achieving fundamental benefits for healthcare providers and patients by improving access to advanced drug treatments.

For his part, Dr. Issam Mohamed, CEO of Mubadala Bio, said that the company is committed to strengthening the drug production system in the UAE, and that it ensures, by investing in national capabilities and providing basic and advanced drugs for the treatment of oncology, that modern treatments are constantly available to patients who depend on them.

In turn, Hamad Hussein Al Marzouqi, Executive Vice President of Mubadala Bio, said that the company is focusing its efforts on meeting the most prominent medical needs in the UAE, and that the new facility, with its international specifications, and the launch of the three advanced drugs for treating oncology, not only reflect the expansion of its production capabilities, but also its firm commitment to advancing national pharmaceutical innovation and providing reliable, high-quality medicines that ensure their access to patients throughout the country.

The establishment of the new facility and the production of oncology drugs locally is part of the comprehensive “Bio Mubadala” strategy to enhance national drug security and ensure the sustainability of the provision of basic treatments, in line with the UAE’s trends towards building an advanced and sustainable pharmaceutical sector.

• For more: Follow Khaleejion 24 Arabic, Khaleejion 24 English, Khaleejion 24 Live, and for social media follow us on Facebook and Related